CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation is pleased to announce an opportunity to purchase shares in a $20,000,000 Private Investment in a Public Entity (PIPE). PixarBio has secured a public entity and we are in the process of merging with that entity so we expect to be publicly traded on the OTC-QB by the end of August 2016. We intend to up-list to the NASDAQ in early 2017.
PixarBio Corp the inventors of NeuroReleaseTM, a Morphine Strength, a non-addictive, non-opioid, non-opiate, but Morphine strength pain treatment is going public. The use of the proceeds will be to maintain the momentum of the NeuroReleaseTM Pain platform toward FDA approval in 2018 through building teams and facilities for NeuroRelease Post-op pain and 3-Day “sprinkle-on” NeuroRelease for wound pain.
PixarBio Corporation’s August 2016 PIPE will raise between $20,000,000 and $30,000,000 through the issuance of 10,000,000 shares at $2.00 per share. An oversubscription maximum to $30,000,000 will also be raised at $2.00/share. In addition, a seven-year warrant priced at $4.50, PixarBio may raise an additional $45,000,000 over the next seven years. The offering is being led by the founders who will invest over $1,000,000 cash at the PIPE offering priced at $2.00/share.
Interested Accredited investors as defined under the US Securities Act of 1933 are invited to download the offering package by completing the form in the public offering link below:
Please click https://pixarbio.com/welcome-page/?accredited
Accredited investors can also email email@example.com for details on the PIPE offering.
Market Desperation For Non-Opiate, Non Addictive Pain Treatment Options
In July 2016, PixarBio created our Clinical Advisory Board and quickly signed 7 of the top 20 knee and hip society members in the USA as advisors to our clinical studies. Using the FDA 505(b)(2) pathway will speed products through the FDA because both components of our New Drug are already FDA approved with approximately 50 years of Safety Data available to the FDA so the safety profiles of NeuroRelease are known to the FDA. Our team comprises leaders of Hospital for Special Surgery, Cleveland Clinic, Rush-Chicago, OrthoCarolina, Hoag Los Angeles, Andrews Institute (Tommy John Surgery pros), and other top clinical research centers.
NeuroReleaseTM Platform, non-addictive, non-opiate pain platform
NeuroReleaseTM is a morphine strength platform, and non-addictive pain treatment for the hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment is expected in 2018. A major benefit of NeuroReleaseTM is there is no effect on locomotion nerve fibers, so patients can still control their locomotion nerve fibers movements and move around with a morphine strength treatment that is non-addictive. NeuroReleaseTM only effects sensory or pain signaling nerve fibers.
"Sprinkle-On" Version of NeuroReleaseTM
Like Vancomycin, an antibiotic that is sprinkled into incisions and wounds to reduce infection, NeuroReleaseTM can be sprinkled into incisions and wounds to provide pain treatment. We envision "Sprinkle On" NeuroReleaseTM, a 3-day sterile powder that can be used in a range of non-hospital settings such as the battlefield where the current use of morphine leads to immobilized soldiers. Since NeuroReleaseTM does not affect locomotion fibers, soldiers can move themselves to safety. Emergency room trauma is a logical application in the clinic and "Sprinkle On" NeuroReleaseTM will be a welcomed new pain treatment option for physicians performing surgery.
PixarBio NeuroReleaseTM pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroReleaseTM is biodegradable, and it's non-toxic so NeuroReleaseTM is the only non-opiate under review at the FDA that can be re-injected to extend treatment timelines. "NeuroReleaseTM represents the holy-grail of pain treatment, and the quality of the KOL's we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroReleaseTM", said CEO Frank Reynolds.
Last month PixarBio Corporation was awarded the Boston Business Journal's "2016 Best Places to Work". The award recognizes PixarBio as one of the region's best firms, offering the greatest professional opportunities and work environments to innovate; the company is excited to bring "Sprinkle On" NeuroReleaseTM to market in 2019.
About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT's Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione, Haining Dai, Xi Chen, and Dr. Amer Khalil. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. For more information visit www.pixarbio.com